CBD has lower affinity for CB receptors. It functions being an antagonist or partial antagonist at endogenous cannabinoid receptors (both CB1 and CB2 receptor types and other G-protein-coupled receptors [GPCRs]) by inhibiting whole binding of immediate ligands, and could act generally at alloste